Zobrazeno 1 - 10
of 621
pro vyhledávání: '"TROP2"'
Autor:
Irene Testi, Giulia Claire Giudice, Giuseppe Salfi, Martino Pedrani, Sara Merler, Fabio Turco, Luigi Tortola, Ursula Vogl
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1326-1364 (2024)
Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatme
Externí odkaz:
https://doaj.org/article/50345d19217b432891d671f63e69aa3f
Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy
Autor:
Jianguo Lai, Shuxuan Deng, Jiyuan Cao, Yongqi Ren, Zanmei Xu, Xiaofang Qi, Mian Xu, Ning Liao
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Purpose Trop2, a cell membrane glycoprotein, is overexpressed in almost all epithelial cancers. This study aimed to explore the mutational characteristics and significance of Trop2 in breast cancer (BC). Methods Patients diagnosed with BC (n
Externí odkaz:
https://doaj.org/article/2c8c60b6bed845d9a6bae5efa665f11e
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-17 (2024)
Abstract Human trophoblastic cell surface antigen 2 (Trop2) is a glycoprotein, a cellular marker of trophoblastic and stem cells, and a calcium signaling transducer involved in several signaling pathways, leading to the proliferation, invasion, and m
Externí odkaz:
https://doaj.org/article/7214982032d74db3801c36504f675c87
Autor:
Lulu CHEN, Qibin SONG
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 7, Pp 535-541 (2024)
Approximately 50% of patients with non-small-cell lung cancer (NSCLC) are diagnosed at advanced stages and face a challenging prognosis despite the integration of targeted therapies, immunotherapy, and systemic chemotherapy into current standard care
Externí odkaz:
https://doaj.org/article/403c728e5e2e4a55b344b317307fa61a
Publikováno v:
Breast, Vol 78, Iss , Pp 103830- (2024)
Breast cancer has become the most prevalent malignant tumor worldwide and remains one of the leading causes of cancer-related mortality among women globally. The prognosis for patients with metastatic breast cancer remains poor, necessitating the exp
Externí odkaz:
https://doaj.org/article/249ee2a0b2ce4c5da4d86bce66894ef4
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Breast cancer (BC) remains a leading cause of cancer-related mortality in women, with hormone receptor-positive (HR+) tumors accounting for a significant proportion of cases. Despite advancements in endocrine therapy (ET), resistance remains a challe
Externí odkaz:
https://doaj.org/article/0fd5239bc1054a4aae535d7b83a04a96
Autor:
Wei Huang, You Zhang, Min Cao, Yanfei Wu, Feng Jiao, Zhaohui Chu, Xinyuan Zhou, Lianghua Li, Dongsheng Xu, Xinbing Pan, Yihui Guan, Gang Huang, Jianjun Liu, Fang Xie, Weijun Wei
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 5, Pp 1143-1161 (2024)
Abstract Accurately predicting and selecting patients who can benefit from targeted or immunotherapy is crucial for precision therapy. Trophoblast cell surface antigen 2 (Trop2) has been extensively investigated as a pan-cancer biomarker expressed in
Externí odkaz:
https://doaj.org/article/61f3e8e3204c445386f683d1dd292f12
Autor:
Wenjuan Tang, Yu Hu, Kaihui Tu, Zhengyan Gong, Man Zhu, Tianfeng Yang, Ammar Sarwar, Bingling Dai, Dongdong Zhang, Yingzhuan Zhan, Yanmin Zhang
Publikováno v:
Journal of Advanced Research, Vol 58, Iss , Pp 193-210 (2024)
Introduction: Tumor-associated calcium signal transducer 2 (Trop2) has been used as a transport gate for cytotoxic agents into cells in antibody–drug conjugate designs because of its expression in a wide range of solid tumors. However, the specific
Externí odkaz:
https://doaj.org/article/877e82d55c484d0aadcaadee5090206b
Autor:
Sebastian Foersch, Maxime Schmitt, Anne‐Sophie Litmeyer, Markus Tschurtschenthaler, Thomas Gress, Detlef K Bartsch, Nicole Pfarr, Katja Steiger, Carsten Denkert, Moritz Jesinghaus
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 5, Pp n/a-n/a (2024)
Abstract Antibody–drug conjugates (ADCs) directed to trophoblast cell surface antigen 2 (TROP2) have gained approval as a therapeutic option for advanced triple‐negative breast cancer, and TROP2 expression has been linked to unfavourable outcomes
Externí odkaz:
https://doaj.org/article/8a36804c34c64ace9a0a2bc6238a569b
Autor:
Jiani Wang, Zhongsheng Tong, Yinuo Tan, Yehui Shi, Yun Wu, Qing Zhou, Xiaoyan Xing, Xiaomei Chen, Fuming Qiu, Fei Ma
Publikováno v:
Cell Reports Medicine, Vol 5, Iss 9, Pp 101707- (2024)
Summary: This phase 1a study assesses ESG401 in patients with heavily pretreated locally advanced or metastatic solid tumors, focusing on metastatic breast cancer. Forty patients are enrolled: three experience dose-limiting toxicities, establishing t
Externí odkaz:
https://doaj.org/article/736f4c38ba8e4e2ca5a20e6083c652d7